Delcath Systems (STU:DV3R) Current Accrued Expense : €1.45 Mil (As of Mar. 2025)

View and export this data going back to 2012. Start your Free Trial

What is Delcath Systems Current Accrued Expense?

Delcath Systems's Current Accrued Expense for the quarter that ended in Mar. 2025 was €1.45 Mil.

Delcath Systems's quarterly Current Accrued Expense declined from Sep. 2024 (€2.39 Mil) to Dec. 2024 (€1.31 Mil) but then increased from Dec. 2024 (€1.31 Mil) to Mar. 2025 (€1.45 Mil).

Delcath Systems's annual Current Accrued Expense declined from Dec. 2022 (€3.44 Mil) to Dec. 2023 (€3.04 Mil) and declined from Dec. 2023 (€3.04 Mil) to Dec. 2024 (€1.31 Mil).

Delcath Systems Current Accrued Expense Historical Data

The historical data trend for Delcath Systems's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems Current Accrued Expense Chart

Delcath Systems Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

0.78

1.50

3.44

3.04

1.31

Delcath Systems Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															2.60	1.97	2.39	1.31	1.45

Delcath Systems Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Delcath Systems Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Delcath Systems's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Delcath Systems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (STU:DV3R) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

DCTH:USA DV3R:Germany

Address

566 Queensbury Avenue, Queensbury, NY, USA, 12804

Website

https://www.delcath.com

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Delcath Systems Headlines

No Headlines